IDBS and Alchemi announced a partnership designed to accelerate biopharma regulatory filings by linking AI agents to data governed in the IDBS Polar platform. The companies’ pitch targets a key bottleneck in CMC documentation, where manual assembly of traceable process histories can take months. The integration is meant to preserve compliance chain-of-custody by drafting submission documents from validated data captured at creation. IDBS said the workflow supports human-in-the-loop review and sign-off, keeping technical documentation aligned with regulatory expectations. Alchemi reported that in customer deployments, teams produced certain CMC documents up to 70% faster using its agents, while IDBS argued current AI tools often break compliance by extracting data outside validated systems. Executives framed the partnership as an effort to keep regulatory milestones moving without compromising auditability—an issue that has increasingly shaped how regulated AI is deployed across clinical development.